What impact does the collapse of Novartis have on my investments in the third pillar?

If your pillar 3a or 3b fund includes Novartis shares or Swiss equity funds, Tuesday's collapse reduced the net worth of your position. The entity depends on the percentage of Novartis shares in the fund. Contact the fund manager to verify the exact exposure. In the medium to long term, many experts recommend staying the course rather than selling in a panic, as stock markets historically recover from crashes.

Does a collapse of CHF 24 billion pose a systemic risk to Switzerland?

No, although significant. By way of comparison, the minimum euro/franc exchange rate abolished by the SNB in 2015 had burned 17 billion. The collapse of Novartis is bigger, but it remains a company-focused event. However, as Novartis is an important component of the SMI index, the event has an effect on the overall performance of the Swiss Stock Exchange.

Should I Sell My Novartis Shares After Tuesday's Crash?

There is no universal answer. It depends on: (a) your long-term investment strategy, (b) the importance of Novartis in your portfolio, (c) your risk tolerance. Investors should consult a financial advisor before making impulsive decisions based on short-term volatility.

Which Swiss pharmaceutical companies other than Novartis could I consider?

Roche is the other large Swiss multinational pharmaceutical company listed on the stock exchange and also a member of the SMI index. Both companies are exposed to drug development risks, but a diversification between the two stocks reduces the risk focused on a single failure.

Black Day for Novartis: 10% Collapse (cross-border guide)

Di Redazione Frontaliere Ticino · Published on 8 September 2026

Swiss trading floor with stock market data displayed on screens at dawn, reflecting the importance of Switzerland's financial markets.

Novartis shares plummet by more than 10% in a day. Lost capitalisation: CHF 24 billion. Two failures in clinical research shake the Swiss pharmaceutical giant.

Context

In brief

Tuesday: Novartis collapses by over 10% on the stock exchange
Lost 24 billion CHF in market capitalization in a single day
Cause: two major failures in clinical research

Key facts

What: Historic collapse of Novartis stock due to two failures in clinical trials
When: Tuesday, from a peak on September 3 (132.68 CHF) to a low (112.06 CHF)
Where: Swiss stock exchange (Basel-based company)
Who: Novartis, Swiss pharmaceutical giant
Amount: Market capitalization reduced from 239 to 215 billion CHF (-24 billion)

Tuesday was a dark day for Novartis. The Basel-based pharmaceutical giant saw its shares plummet by over 10% in the morning, touching a low of 112.06 francs with a loss of almost 13 francs per share. A hemorrhage that, in terms of market value, translates to approximately 24 billion francs evaporated in a single day, bringing capitalization down from 239 to approximately 215 billion francs.

The fall is even more staggering when you consider that just a week earlier, on September 3, the stock had reached an all-time high of 132.68 francs. In one week, Novartis lost over 13% of its market value — a performance that directly impacts the portfolios of thousands of Swiss investors who hold the stock, either directly or through mutual funds or pension instruments.

According to data compiled by the AWP agency, Tuesday's collapse is destined to go down in the annals as the worst daily collapse ever recorded for Novartis, far surpassing previous negative records. It is an event that marks a line in the history of the Swiss stock market, with dimensions even greater than previous financial shocks.

…

Operational details

An unprecedented collapse. Tuesday's crash represents not only the worst day in Novartis' history, but one of the most significant events in the Swiss stock market in recent years. To understand the severity of what happened, it is enough to compare it with other financial crises that have shaken global markets.

Comparison with previous crises

In January 2015, when the Swiss National Bank (SNB) decided to end the minimum euro/franc exchange rate, the Swiss market had suffered a loss of 17 billion francs. In March 2020, the arrival of Covid had an impact of 16 billion francs. Even the financial crisis of October 2008 had caused a decline of just over 10 billion francs.

With its 24 billion francs lost in a single day, Novartis has surpassed all these precedents. This is an extreme volatility that directly affects anyone who has investments linked to the shares of the Basel pharmaceutical giant, whether through mutual funds, direct stock portfolios, or finally through the third pillar (3a/3b) or occupational pension (LPP).

Impact on Swiss investors and savers

For Swiss savers who have invested in the third pillar or pension funds that include Novartis shares, Tuesday's day represents a significant loss of assets. Novartis, together with Roche and other major industrials, is an important component of the SMI (Swiss Market Index), the main index of the Swiss stock exchange. Such a massive collapse has direct effects on the overall performance of the portfolio of anyone who has investments in Swiss equities.

…

Key points

After such a volatile event, what should a Swiss saver do?

Analyze your portfolio and rebalance

The first action is to take stock of your exposure to Novartis. If you hold the stock directly, or if you invest in mutual funds that include a significant share of Novartis shares, now is the time for a thorough check. Concentration of risk in a single stock – no matter how important – can expose you to significant losses, as seen on Tuesday.

A classic approach involves rebalancing your portfolio according to your original asset allocation strategy. If before the Novartis crisis, for example, it represented 10% of your portfolio, the 10%+ drop means that its relative weight has decreased (for example to 9%). Rebalancing means realigning the proportion according to the initial plan.

Consult a financial advisor

Savers with complex or significant portfolios should consult a financial advisor or their bank to evaluate:

Overall exposure to the pharmaceutical sector
Geographic diversification and by asset class
Tax implications of any sales (stamp duties, direct federal tax on capital gains)
Strategies to protect value in the long term

Available tools

For those investing in the third pillar or occupational pensions, it is possible to contact the fund manager to understand how the fall of Novartis affects the net value of your investment and whether automatic rebalancing options are available. Furthermore, using specialized portfolio tools and consulting experts can help you plan an investment strategy more resilient to future market shocks.

…

Frequently Asked Questions

What impact does the collapse of Novartis have on my investments in the third pillar?: If your pillar 3a or 3b fund includes Novartis shares or Swiss equity funds, Tuesday's collapse reduced the net worth of your position. The entity depends on the percentage of Novartis shares in the fund. Contact the fund manager to verify the exact exposure. In the medium to long term, many experts recommend staying the course rather than selling in a panic, as stock markets historically recover from crashes.
Does a collapse of CHF 24 billion pose a systemic risk to Switzerland?: No, although significant. By way of comparison, the minimum euro/franc exchange rate abolished by the SNB in 2015 had burned 17 billion. The collapse of Novartis is bigger, but it remains a company-focused event. However, as Novartis is an important component of the SMI index, the event has an effect on the overall performance of the Swiss Stock Exchange.
Should I Sell My Novartis Shares After Tuesday's Crash?: There is no universal answer. It depends on: (a) your long-term investment strategy, (b) the importance of Novartis in your portfolio, (c) your risk tolerance. Investors should consult a financial advisor before making impulsive decisions based on short-term volatility.
Which Swiss pharmaceutical companies other than Novartis could I consider?: Roche is the other large Swiss multinational pharmaceutical company listed on the stock exchange and also a member of the SMI index. Both companies are exposed to drug development risks, but a diversification between the two stocks reduces the risk focused on a single failure.